Ophthalmic anti-inflammatory suspension

This page covers all Ophthalmic anti-inflammatory suspension drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds.

Phase 3 pipeline (1)

• KPI-121 0.25% Ophthalmic Suspension · Kala Pharmaceuticals, Inc. · Ophthalmology
  KPI-121 is a suspension formulation designed to reduce ocular inflammation and improve tear film stability in dry eye disease through sustained ocular surface contact.

Patent intelligence

• ophthalmic anti inflammatory suspension patent landscape — aggregated cliff calendar, attackable patents, originator estates